Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reuse of single-use devices

This article was originally published in The Gray Sheet

Executive Summary

Association of Disposable Device Manufacturers submits simulated direct final rule to FDA that would require reprocessors to comply with existing premarket regulations, rather than follow the separate three-tiered classification system outlined in FDA's proposed strategy, issued Nov. 2 (1"The Gray Sheet" Nov. 8, p. 3). While FDA would exempt reprocessed SUDs deemed "low-risk" from premarket requirements, ADDM maintains that makers of all reprocessed Class I and Class II SUDs should either be required to submit 510(k)s or file petitions for 510(k) exemption. ADDM's mock reg also would shorten FDA's proposed grace period for reprocessors - requiring PMAs for reprocessed Class III SUDs immediately, 510(k)s for Class II devices in six months, and for Class I devices in nine months

You may also be interested in...



Risk Classification Governs SUD Reprocessor Premarket Requirements - FDA

FDA's current resource levels are insufficient to carry out inspections of health care facilities that reprocess medical devices intended for single use, FDA staffers believe.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel